Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation

NCT03560908 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped No enough eligable participants enrolled

Conditions

Relapsed AML
T(8;21)
C-KIT Mutation

Interventions

DRUG: Dasatinib

Sponsor

Institute of Hematology & Blood Diseases Hospital, China